Salivary adenoid cystic carcinoma in Denmark 1990-2005: Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA)

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Salivary adenoid cystic carcinoma in Denmark 1990-2005 : Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA). / Bjørndal, Kristine; Krogdahl, Annelise; Therkildsen, Marianne H; Charabi, Birgitte; Kristensen, Claus A; Andersen, Elo; Schytte, Sten; Primdahl, Hanne; Johansen, Jørgen; Pedersen, Henrik B.; Andersen, Lisbeth J; Godballe, Christian.

In: Oral Oncology, Vol. 51, No. 12, 12.2015, p. 1138-42.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bjørndal, K, Krogdahl, A, Therkildsen, MH, Charabi, B, Kristensen, CA, Andersen, E, Schytte, S, Primdahl, H, Johansen, J, Pedersen, HB, Andersen, LJ & Godballe, C 2015, 'Salivary adenoid cystic carcinoma in Denmark 1990-2005: Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA)', Oral Oncology, vol. 51, no. 12, pp. 1138-42. https://doi.org/10.1016/j.oraloncology.2015.10.002

APA

Bjørndal, K., Krogdahl, A., Therkildsen, M. H., Charabi, B., Kristensen, C. A., Andersen, E., Schytte, S., Primdahl, H., Johansen, J., Pedersen, H. B., Andersen, L. J., & Godballe, C. (2015). Salivary adenoid cystic carcinoma in Denmark 1990-2005: Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncology, 51(12), 1138-42. https://doi.org/10.1016/j.oraloncology.2015.10.002

Vancouver

Bjørndal K, Krogdahl A, Therkildsen MH, Charabi B, Kristensen CA, Andersen E et al. Salivary adenoid cystic carcinoma in Denmark 1990-2005: Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncology. 2015 Dec;51(12):1138-42. https://doi.org/10.1016/j.oraloncology.2015.10.002

Author

Bjørndal, Kristine ; Krogdahl, Annelise ; Therkildsen, Marianne H ; Charabi, Birgitte ; Kristensen, Claus A ; Andersen, Elo ; Schytte, Sten ; Primdahl, Hanne ; Johansen, Jørgen ; Pedersen, Henrik B. ; Andersen, Lisbeth J ; Godballe, Christian. / Salivary adenoid cystic carcinoma in Denmark 1990-2005 : Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA). In: Oral Oncology. 2015 ; Vol. 51, No. 12. pp. 1138-42.

Bibtex

@article{be7c05cf867948d0804d474423bd664d,
title = "Salivary adenoid cystic carcinoma in Denmark 1990-2005: Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA)",
abstract = "AIM: To describe outcome and prognostic factors, including the effect of radiotherapy, in a consecutive national series of salivary gland adenoid cystic carcinomas.METHODS: From the national Danish salivary gland carcinoma database in the structure of DAHANCA, 201 patients diagnosed with adenoid cystic carcinoma, and treated with a curative intent, were identified in the period between 1990 and 2005. Variables necessary for statistical analyses were extracted from the database.RESULTS: The 10-year crude survival and disease specific survival rates were 58% and 75%, respectively. The 10-year locoregional control rate was 70%, and 36% of patients experienced a recurrence during follow-up (median 7.5 years); 18% developed distant metastases (most commonly to the lungs). In multivariate analysis, stage and margin status were both important factors with regards to survival and locoregional control. Radiotherapy did not improve survival, but it did improve the locoregional control rate.CONCLUSIONS: The treatment of choice is surgery with as wide margins as possible including elective, selective neck dissection. Adjuvant radiotherapy should be considered in patients with incomplete tumor resection, high disease stages, and tumors with a solid growth pattern.",
author = "Kristine Bj{\o}rndal and Annelise Krogdahl and Therkildsen, {Marianne H} and Birgitte Charabi and Kristensen, {Claus A} and Elo Andersen and Sten Schytte and Hanne Primdahl and J{\o}rgen Johansen and Pedersen, {Henrik B.} and Andersen, {Lisbeth J} and Christian Godballe",
note = "Copyright {\textcopyright} 2015 Elsevier Ltd. All rights reserved.",
year = "2015",
month = dec,
doi = "10.1016/j.oraloncology.2015.10.002",
language = "English",
volume = "51",
pages = "1138--42",
journal = "Oral Oncology Extra",
issn = "1741-9409",
publisher = "Pergamon Press",
number = "12",

}

RIS

TY - JOUR

T1 - Salivary adenoid cystic carcinoma in Denmark 1990-2005

T2 - Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA)

AU - Bjørndal, Kristine

AU - Krogdahl, Annelise

AU - Therkildsen, Marianne H

AU - Charabi, Birgitte

AU - Kristensen, Claus A

AU - Andersen, Elo

AU - Schytte, Sten

AU - Primdahl, Hanne

AU - Johansen, Jørgen

AU - Pedersen, Henrik B.

AU - Andersen, Lisbeth J

AU - Godballe, Christian

N1 - Copyright © 2015 Elsevier Ltd. All rights reserved.

PY - 2015/12

Y1 - 2015/12

N2 - AIM: To describe outcome and prognostic factors, including the effect of radiotherapy, in a consecutive national series of salivary gland adenoid cystic carcinomas.METHODS: From the national Danish salivary gland carcinoma database in the structure of DAHANCA, 201 patients diagnosed with adenoid cystic carcinoma, and treated with a curative intent, were identified in the period between 1990 and 2005. Variables necessary for statistical analyses were extracted from the database.RESULTS: The 10-year crude survival and disease specific survival rates were 58% and 75%, respectively. The 10-year locoregional control rate was 70%, and 36% of patients experienced a recurrence during follow-up (median 7.5 years); 18% developed distant metastases (most commonly to the lungs). In multivariate analysis, stage and margin status were both important factors with regards to survival and locoregional control. Radiotherapy did not improve survival, but it did improve the locoregional control rate.CONCLUSIONS: The treatment of choice is surgery with as wide margins as possible including elective, selective neck dissection. Adjuvant radiotherapy should be considered in patients with incomplete tumor resection, high disease stages, and tumors with a solid growth pattern.

AB - AIM: To describe outcome and prognostic factors, including the effect of radiotherapy, in a consecutive national series of salivary gland adenoid cystic carcinomas.METHODS: From the national Danish salivary gland carcinoma database in the structure of DAHANCA, 201 patients diagnosed with adenoid cystic carcinoma, and treated with a curative intent, were identified in the period between 1990 and 2005. Variables necessary for statistical analyses were extracted from the database.RESULTS: The 10-year crude survival and disease specific survival rates were 58% and 75%, respectively. The 10-year locoregional control rate was 70%, and 36% of patients experienced a recurrence during follow-up (median 7.5 years); 18% developed distant metastases (most commonly to the lungs). In multivariate analysis, stage and margin status were both important factors with regards to survival and locoregional control. Radiotherapy did not improve survival, but it did improve the locoregional control rate.CONCLUSIONS: The treatment of choice is surgery with as wide margins as possible including elective, selective neck dissection. Adjuvant radiotherapy should be considered in patients with incomplete tumor resection, high disease stages, and tumors with a solid growth pattern.

U2 - 10.1016/j.oraloncology.2015.10.002

DO - 10.1016/j.oraloncology.2015.10.002

M3 - Journal article

C2 - 26476712

VL - 51

SP - 1138

EP - 1142

JO - Oral Oncology Extra

JF - Oral Oncology Extra

SN - 1741-9409

IS - 12

ER -

ID: 162751363